The prostate cancer prevention trial

Current status and lessons learned

Ian M. Thompson, Margaret Kouril, Eric A. Klein, Charles A. Coltman, Anne Ryan, Phyllis Goodman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The Prostate Cancer Prevention Trial is the first phase 3 prevention trial for prostate cancer in the United States. The implementation of a large, randomized trial has provided a wealth of information that will aid in future cancer chemopreventive studies in US men. The experience from the implementation of the Prostate Cancer Prevention Trial was reviewed. Lessons learned from the study include: (1) US men are willing to enroll in prevention trials; (2) participants in chemoprevention trials are well educated and healthy; (3) the successful cancer prevention trial is viewed by participants as a "men's health trial"; (4) data management and discipline coordination at participating institutions are critical; (5) study design change is commonly required owing to changes in clinical practice over the course of the trial; and (6) training of institutional staff is essential. With proper design, robust data management, and a flexible staff, large-scale randomized chemoprevention trials can be accomplished in the United States. With the extraordinary number of potential agents, it is expected that much will be accomplished with this strategy in the near future.

Original languageEnglish (US)
Pages (from-to)230-234
Number of pages5
JournalUrology
Volume57
Issue number4 SUPPL. 1
StatePublished - 2001

Fingerprint

Prostatic Neoplasms
Chemoprevention
Men's Health
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Thompson, I. M., Kouril, M., Klein, E. A., Coltman, C. A., Ryan, A., & Goodman, P. (2001). The prostate cancer prevention trial: Current status and lessons learned. Urology, 57(4 SUPPL. 1), 230-234.

The prostate cancer prevention trial : Current status and lessons learned. / Thompson, Ian M.; Kouril, Margaret; Klein, Eric A.; Coltman, Charles A.; Ryan, Anne; Goodman, Phyllis.

In: Urology, Vol. 57, No. 4 SUPPL. 1, 2001, p. 230-234.

Research output: Contribution to journalArticle

Thompson, IM, Kouril, M, Klein, EA, Coltman, CA, Ryan, A & Goodman, P 2001, 'The prostate cancer prevention trial: Current status and lessons learned', Urology, vol. 57, no. 4 SUPPL. 1, pp. 230-234.
Thompson IM, Kouril M, Klein EA, Coltman CA, Ryan A, Goodman P. The prostate cancer prevention trial: Current status and lessons learned. Urology. 2001;57(4 SUPPL. 1):230-234.
Thompson, Ian M. ; Kouril, Margaret ; Klein, Eric A. ; Coltman, Charles A. ; Ryan, Anne ; Goodman, Phyllis. / The prostate cancer prevention trial : Current status and lessons learned. In: Urology. 2001 ; Vol. 57, No. 4 SUPPL. 1. pp. 230-234.
@article{7941ebf4f4384c678d81ff4b4b3f200b,
title = "The prostate cancer prevention trial: Current status and lessons learned",
abstract = "The Prostate Cancer Prevention Trial is the first phase 3 prevention trial for prostate cancer in the United States. The implementation of a large, randomized trial has provided a wealth of information that will aid in future cancer chemopreventive studies in US men. The experience from the implementation of the Prostate Cancer Prevention Trial was reviewed. Lessons learned from the study include: (1) US men are willing to enroll in prevention trials; (2) participants in chemoprevention trials are well educated and healthy; (3) the successful cancer prevention trial is viewed by participants as a {"}men's health trial{"}; (4) data management and discipline coordination at participating institutions are critical; (5) study design change is commonly required owing to changes in clinical practice over the course of the trial; and (6) training of institutional staff is essential. With proper design, robust data management, and a flexible staff, large-scale randomized chemoprevention trials can be accomplished in the United States. With the extraordinary number of potential agents, it is expected that much will be accomplished with this strategy in the near future.",
author = "Thompson, {Ian M.} and Margaret Kouril and Klein, {Eric A.} and Coltman, {Charles A.} and Anne Ryan and Phyllis Goodman",
year = "2001",
language = "English (US)",
volume = "57",
pages = "230--234",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - The prostate cancer prevention trial

T2 - Current status and lessons learned

AU - Thompson, Ian M.

AU - Kouril, Margaret

AU - Klein, Eric A.

AU - Coltman, Charles A.

AU - Ryan, Anne

AU - Goodman, Phyllis

PY - 2001

Y1 - 2001

N2 - The Prostate Cancer Prevention Trial is the first phase 3 prevention trial for prostate cancer in the United States. The implementation of a large, randomized trial has provided a wealth of information that will aid in future cancer chemopreventive studies in US men. The experience from the implementation of the Prostate Cancer Prevention Trial was reviewed. Lessons learned from the study include: (1) US men are willing to enroll in prevention trials; (2) participants in chemoprevention trials are well educated and healthy; (3) the successful cancer prevention trial is viewed by participants as a "men's health trial"; (4) data management and discipline coordination at participating institutions are critical; (5) study design change is commonly required owing to changes in clinical practice over the course of the trial; and (6) training of institutional staff is essential. With proper design, robust data management, and a flexible staff, large-scale randomized chemoprevention trials can be accomplished in the United States. With the extraordinary number of potential agents, it is expected that much will be accomplished with this strategy in the near future.

AB - The Prostate Cancer Prevention Trial is the first phase 3 prevention trial for prostate cancer in the United States. The implementation of a large, randomized trial has provided a wealth of information that will aid in future cancer chemopreventive studies in US men. The experience from the implementation of the Prostate Cancer Prevention Trial was reviewed. Lessons learned from the study include: (1) US men are willing to enroll in prevention trials; (2) participants in chemoprevention trials are well educated and healthy; (3) the successful cancer prevention trial is viewed by participants as a "men's health trial"; (4) data management and discipline coordination at participating institutions are critical; (5) study design change is commonly required owing to changes in clinical practice over the course of the trial; and (6) training of institutional staff is essential. With proper design, robust data management, and a flexible staff, large-scale randomized chemoprevention trials can be accomplished in the United States. With the extraordinary number of potential agents, it is expected that much will be accomplished with this strategy in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0035320033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035320033&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 230

EP - 234

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4 SUPPL. 1

ER -